Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration.
In the planning of MRI protocols to monitor disease activity in multiple sclerosis (MS), the clinical subtype needs to be considered. In this serial gadolinium-enhanced MRI study, we demonstrated differences between patients with early relapsing/remitting MS and benign MS in both the production of new lesions and the occurrence of enhancement.
Thompson
A J
AJ
NMR Research Group, Institute of Neurology, Queen Square, London, England.
Miller
D
D
Youl
B
B
MacManus
D
D
Moore
S
S
Kingsley
D
D
Kendall
B
B
Feinstein
A
A
McDonald
W I
WI
D000328:Adult; D003287:Contrast Media; D019786:Gadolinium DTPA; D006801:Humans; D007089:Image Enhancement; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000503:physiopathology; D009942:Organometallic Compounds; D004369:Pentetic Acid; D012008:Recurrence; D013997:Time Factors
D003287:Contrast Media; D009942:Organometallic Compounds; D004369:Pentetic Acid; D019786:Gadolinium DTPA